

Troels Korshøj Bergmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1587172/publications.pdf>

Version: 2024-02-01

36
papers

1,814
citations

448610

19
h-index

406436

35
g-index

36
all docs

36
docs citations

36
times ranked

3536
citing authors

#	ARTICLE	IF	CITATIONS
1	No significant influence of OCT1 genotypes on the pharmacokinetics of morphine in adult surgical patients. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2022, 130, 93-102.	1.2	5
2	BCPT policy for experimental and clinical studies. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, 128, 4-8.	1.2	248
3	Oral and intravenous pharmacokinetics of metformin with and without oral codeine intake in healthy subjects: A cross-over study. <i>Clinical and Translational Science</i> , 2021, 14, 2408-2419.	1.5	6
4	Drug-drug cross contamination in the Swisslog fully automated medication handling system. <i>European Journal of Hospital Pharmacy</i> , 2021, 28, 229-230.	0.5	1
5	Editorial: Therapeutic Drug Monitoring in Solid Organ Transplantation. <i>Frontiers in Pharmacology</i> , 2021, 12, 815117.	1.6	4
6	Four phase 1 trials to evaluate the safety and pharmacokinetic profile of single and repeated dosing of SCO-101 in adult male and female volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 127, 329-337.	1.2	6
7	A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 791-798.	1.1	17
8	Response to Letter to the Editor concerning "Progression-free survival (PFS) in oncology: Caveat emptor!". <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019, 124, 239-239.	1.2	0
9	Progression-free survival in oncology: Caveat emptor!. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019, 124, 240-244.	1.2	4
10	Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review. <i>Clinical Pharmacokinetics</i> , 2018, 57, 7-19.	1.6	130
11	Basic & Clinical Pharmacology & Toxicology Policy for Experimental and Clinical studies. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 123, 233-235.	1.2	256
12	Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 547-553.	2.3	27
13	The Pharmacogenetics of Tacrolimus in Corticosteroid-Sparse Pediatric and Adult Kidney Transplant Recipients. <i>Drugs in R and D</i> , 2017, 17, 279-286.	1.1	14
14	New Drug Interaction: Clopidogrel Associated with Paclitaxel Induced Neuropathy in Cancer Patients. <i>Clinical Therapeutics</i> , 2017, 39, e61.	1.1	1
15	Population Pharmacokinetics of Methylphenidate in Healthy Adults Emphasizing Novel and Known Effects of Several Carboxylesterase 1 (CES1) Variants. <i>Clinical and Translational Science</i> , 2016, 9, 337-345.	1.5	10
16	Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinoma. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 313-315.	1.1	20
17	A Cancer That Went Up in Smoke. <i>Chest</i> , 2016, 149, e65-e67.	0.4	31
18	Tacrolimus pharmacokinetics after kidney transplantation - Influence of changes in haematocrit and steroid dose. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1475-1476.	1.1	3

#	ARTICLE	IF	CITATIONS
19	Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel. <i>Clinical Cancer Research</i> , 2015, 21, 3092-3093.	3.2	9
20	Docetaxel-induced neuropathy: A pharmacogenetic case-control study of 150 women with early-stage breast cancer. <i>Acta Oncologica</i> , 2015, 54, 535-542.	0.8	37
21	Role of cytochrome P450 <i>CYP2C8</i> in paclitaxel metabolism and paclitaxel-induced neurotoxicity. <i>Pharmacogenomics</i> , 2015, 16, 929-937.	0.6	17
22	Exploratory Study of Total and Free Prednisolone Plasma Exposure and Cushingoid Appearance, Quality of Life and Biochemical Toxicity in Adult Male Kidney Transplant Recipients. <i>Clinical Drug Investigation</i> , 2015, 35, 743-750.	1.1	6
23	Population Pharmacokinetics of Tacrolimus in Adult Kidney Transplant Patients. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 62-70.	1.0	70
24	Comparison of the Influence of Cyclosporine and Tacrolimus on the Pharmacokinetics of Prednisolone in Adult Male Kidney Transplant Recipients. <i>Clinical Drug Investigation</i> , 2014, 34, 183-188.	1.1	6
25	Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 509-523.	1.1	67
26	The predictive value of <i>KRAS</i> , <i>NRAS</i> , <i>BRAF</i> , <i>PIK3CA</i> and <i>PTEN</i> for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. <i>Acta Oncologica</i> , 2014, 53, 852-864.	0.8	324
27	CWAS-based association between <i>RWDD3</i> and <i>TECTA</i> variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients. <i>Acta Oncologica</i> , 2013, 52, 871-873.	0.8	24
28	NR1I2 Polymorphisms Are Related to Tacrolimus Dose-Adjusted Exposure and BK Viremia in Adult Kidney Transplantation. <i>Transplantation</i> , 2012, 94, 1025-1032.	0.5	44
29	Clinical Pharmacokinetics and Pharmacodynamics of Prednisolone and Prednisone in Solid Organ Transplantation. <i>Clinical Pharmacokinetics</i> , 2012, 51, 711-741.	1.6	92
30	Impact of <i>ABCB1</i> Variants on Neutrophil Depression: A Pharmacogenomic Study of Paclitaxel in 92 Women with Ovarian Cancer. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012, 110, 199-204.	1.2	36
31	Impact of <i>CYP2C8</i> on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. <i>Pharmacogenomics Journal</i> , 2011, 11, 113-120.	0.9	81
32	Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 693-700.	0.8	70
33	Linkage disequilibrium between the <i>CYP2C19</i> *17 allele and wildtype <i>CYP2C8</i> and <i>CYP2C9</i> alleles: identification of <i>CYP2C</i> haplotypes in healthy Nordic populations. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 1199-1205.	0.8	75
34	No Evidence for Taxane/Platinum Pharmacogenetic Markers: Just Lack of Power?. <i>Journal of Clinical Oncology</i> , 2008, 26, 1903-1904.	0.8	4
35	Duplication of <i>CYP2D6</i> predicts high clearance of desipramine but high clearance does not predict duplication of <i>CYP2D6</i> . <i>European Journal of Clinical Pharmacology</i> , 2001, 57, 123-127.	0.8	24
36	Multiple Hepatic Abscesses Due to <i>Yersinia enterocolitica</i> Infection Secondary to Primary Haemochromatosis. <i>Scandinavian Journal of Gastroenterology</i> , 2001, 36, 891-895.	0.6	45